Zhenqi Fuzheng combined with chemotherapy for advanced stage lung cancer: a meta analysis

Purpose: To evaluate the outcomes (1 year survival rate, the therapeutic effectiveness and safety) of Zhenqi Fuzheng (ZQFZ) plus chemotherapy compared with chemotherapy alone and clarify its current role for stage II or IV of lung cancer. Methods: Eight studies included 450 patients were analyzed with Revman5.2. Fix models were used to evaluate the outcomes of these studies. Results: Patients receiving ZQFZ plus chemotherapy had significant longer 1-year survival (OR=2.03, 95% CI=1.10-3.73 P=0.02). The clinical curative effective rate (OR=1.44, 95% CI=0.92-2.25, P=0.17) could not be seen significant differences between two groups. The grades of KPS (OR=7.37, 95% CI=3.50-15.52, P<0.00001), Leucopenia (OR=0.33, 95% CI=0.19-0.55, P<0.0001) and Gastrointestinal toxicity reaction (OR=0.57, 95% CI=0.36-0.90, P=0.01) of ZQFZ plus chemotherapy group also displayed more favorable result than chemotherapy alone group. Conclusions: ZQFZ combined with chemotherapy in patients with stage II or IV of lung cancer, to some extent, improved the 1-year survival rate and KPS, associated with lower incidence of Leucopenia and Gastrointestinal toxicity reaction, However, The clinical curative effective rate could not be seen significant differences.